Asterand plc - Board Changes
Published: Jul 29, 2011
Martyn has been responsible for guiding the Company though an exciting period in its development, including the acquisition of BioSeek in 2010 which has added significantly to the Company’s growth prospects.
The Company has immediately commissioned a search process for the new CEO. In the meantime Jack Davis, the Company’s Chairman, will take over the role of Interim CEO.
Jack Davis, the Chairman and Interim CEO, said: “Martyn has been a positive influence as CEO over the last four years and we wish him well for the future.”
The Company continues to experience the trading patterns described in the IMS on 17 May 2011 and, not withstanding the historical weighting towards the second half, the Board remains confident in achieving market expectations for the year as a whole.
Jack Davis, Chairman and Interim Chief Executive Officer
Tel: + 44 (0) 1763 211 600 / + 1 (313) 263-0960
John Stchur, Chief Financial Officer As above
Lisa Baderoon / Mark Court / Isabel Podda
Tel: +44 (0) 20 7466 5000
Daniel Stewart & Company plc
Tel: +44 (0) 20 7776 6550
Asterand plc is a leading supplier of high quality human tissue and tissue-based services. Our comprehensive approach to human tissue and research services offers pharmaceutical, biotech and diagnostic companies the unique opportunity to have one company meet all of their human biomaterial needs along the continuum of drug discovery and development. Our mission is to accelerate target discovery and compound validation and enable pharmaceutical and biotechnology companies to take safer and more effective drugs into the market. For more information about Asterand, go to www.asterand.com